ABLYNX RECEIVES EUR 5 MILLION IN MILESTONE PAYMENT FROM ALZHEIMER'S DISEASE COLLABORATION WITH BOEHRINGER INGELHEIM

(Thomson Reuters ONE) -


GHENT, Belgium, 27 June 2011 - Ablynx [Euronext Brussels: ABLX] today announced
that it has earned a ?5 million milestone payment following Boehringer
Ingelheim's decision to initiate development  with the lead Nanobody candidate
that was selected in May 2010.

In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research
and licensing agreement to discover and develop new therapies for Alzheimer's
disease using Ablynx's Nanobodies against a single disease target. The
collaboration has a potential value of $265 million in upfront and milestone
payments plus undisclosed royalties on product sales. Boehringer Ingelheim is
solely responsible for the development, manufacturing and commercialisation of
any products resulting from the collaboration.

"We are delighted that Boehringer Ingelheim is making further progress with the
Nanobody lead candidate which has the potential to be a first-in-class therapy
for Alzheimer's disease and we look forward to this product advancing into the
clinic in 2012. This is the second milestone payment that we have received as
part of our Alzheimer's research collaboration with Boehringer Ingelheim," said
Dr. Edwin Moses, Chairman and CEO of Ablynx. He added: "This programme
illustrates the wide applicability and advantages of our Nanobody platform in
addressing diseases as complex as Alzheimer's."



For more information, please contact Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com





Complete version of the press release:

http://hugin.info/137912/R/1526010/461786.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE

[HUG#1526010]

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 27.06.2011 - 07:01 Uhr
Sprache: Deutsch
News-ID 55860
Anzahl Zeichen: 2636

contact information:
Town:

Ghent

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 147 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"ABLYNX RECEIVES EUR 5 MILLION IN MILESTONE PAYMENT FROM ALZHEIMER'S DISEASE COLLABORATION WITH BOEHRINGER INGELHEIM"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regar ...

GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx